|
|
|
Moderna's 3rd booster jab effective against Covid variants
|
|
|
|
Top Stories |
|
|
|
|
IANS | 07 May, 2021
A third booster shot of US pharmaceutical Moderna's Covid vaccine can
rapidly increase the level of antibodies in previously inoculated
people, according to data from its Phase 2 study.
The Phase 2
trial showed that antibodies produced by a single 50 mg dose of its
booster shot was effective against the original form of the virus, as
well as against two variants of concern first identified in South Africa
(B1351) and Brazil (P1).
"We are encouraged by these new data,
which reinforce our confidence that our booster strategy should be
protective against these newly detected variants," said Stephane Bancel,
Chief Executive Officer of Moderna, in the statement.
The pharma
major's specifically designed second shot against the South Africa
variant, showed even stronger immune response. The preliminary results
have been described preprint in bioRxiv, the company said.
"Our
mRNA platform allows for rapid design of vaccine candidates that
incorporate key virus mutations, potentially allowing for faster
development of future alternative variant-matched vaccines should they
be needed. We will continue to make as many updates to our Covid-19
vaccine as necessary to control the pandemic," Bancel added.
For
the trial, the company involved 40 participants, and they were
administered the third shot six to eight months after taking the
currently given two-shots.
Antibodies from the initial
vaccination were detectable in 37 of those people, but in about half the
participants, the antibodies performed poorly against the variants that
have pummeled South Africa and Brazil. The boosters raised the levels
of the antibodies against both variants, although the boosters were
still slightly less effective than against the original form of the
virus, the New York Times reported.
Pfizer also recently
announced that Covid vaccine recipients will "likely" need a third dose
between six to 12 months after they're fully vaccinated.
The mRNA
platform used in the Pfizer and Moderna vaccines can be readily
tweaked, enabling the companies to produce newer versions within weeks.
Moderna
began modifying its vaccine to combat the variant identified in South
Africa, after reports emerged that the existing vaccines are slightly
less effective against that variant. The variant carries a mutation that
helps the virus sidestep the immune system, the report said.
Moderna
is testing three strategies for enhancing the immunity produced by the
current vaccine: using the current vaccine as a booster; using the
booster designed specifically to combat B1351; and a combination of the
two in a single vaccine, the report said.
|
|
|
|
|
|
|
|
|
|
|
|
|
Customs Exchange Rates |
Currency |
Import |
Export |
US Dollar
|
66.20
|
64.50 |
UK Pound
|
87.50
|
84.65 |
Euro
|
78.25
|
75.65 |
Japanese
Yen |
58.85 |
56.85 |
As on 13 Aug, 2022 |
|
|
Daily Poll |
|
|
PM Modi's recent US visit to redefine India-US bilateral relations |
|
|
|
|
|
Commented Stories |
|
|
|
|
|
|
|
|